Clayton Duncan

Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA.

Brighton Biotech, Inc. provides medical research services. It specializes in acquiring and developing pharmaceutical and biotechnology products intended for the treatment and prevention of serious unmet medical needs. The company was founded in 2010 and is headquartered in New York, NY.

Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria.

Oklahoma Medical Research Foundation provides investment advice. The company was founded in 1946 and is headquartered in Oklahoma City, OK.

Silver Creek Pharmaceuticals, Inc. develops novel regenerative medicines. The firm focuses on treating cardiovascular disease. Its molecules are designed to promote resilience and regeneration of damaged tissues after acute or chronic injury. The company was founded in 2010 and is headquartered in San Francisco, CA.

Blackthorn Therapeutics, Inc. manufactures and markets medicines for neuro developmental disorders. The company is headquartered in San Francisco, CA.

Part of Wave Life Sciences Ltd., Wave Life Sciences USA, Inc. is a company that provides nucleic acid therapeutics. The company is based in Cambridge, MA. The company was founded in 2012 by Gregory L. Verdine, Takeshi Wada. The CEO is Paul B. Bolno.

Perseus Holdings USA LLC markets vaccine platform technology. The company is headquartered in Austin, TX.

Iridia, Inc. operates as a biotechnology company. It offers research and development services. The company was founded by James P. Linton in 2016 and is headquartered in Carlsbad, CA.

Tremeau Pharmaceuticals, Inc. engages in the developing and delivering of non-opioid pain therapies. The firm product includes TRM-201 (rofecoxib). The company was founded by Bradford C. Sippy and Mark H. N. Corrigan in 2016 and is headquartered in Concord, MA.

Iviva Medical, Inc. develops autologous tissue to serve kidney diseases. The company was founded by Harald C Ott and is headquartered in Beverly, MA.

Chorus Labs LLC operates as a software company that creates tools for the modern workplace. Its product Baton is a task and project management application, encouraging users to delegate everything by passing the baton. The company was founded by Justin Reid Briggs and Matthew Sartin in 2012 and is headquartered in Oklahoma City, OK.

Prime Movers Lab LLC (Prime Movers Lab) is a venture capital firm founded in 2018 by Dakin Sloss. The firm is headquartered in Jackson, Wyoming.

Deep Science Ventures Ltd. (Deep Science Ventures) is a venture capital firm founded 2016 by Mark Hammond and Dominic Falcão. The firm is headquartered in Essex, United Kingdom.

Elevian, Inc. develops medicines that restore youthful regenerative capacity. The company was founded by Mark J. F. Allen, Sebastian Giwa, Peter H. Diamandis, Brock C. Reeve, and Luis Alvarez and is headquartered in Allston, MA.

Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million.